These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 18652043)

  • 1. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
    Vranovsky A; Ladicka M; Lakota J
    Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S
    Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
    Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
    Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
    Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
    Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.